EA200600877A1 - Наночастицы для доставки лекарств - Google Patents

Наночастицы для доставки лекарств

Info

Publication number
EA200600877A1
EA200600877A1 EA200600877A EA200600877A EA200600877A1 EA 200600877 A1 EA200600877 A1 EA 200600877A1 EA 200600877 A EA200600877 A EA 200600877A EA 200600877 A EA200600877 A EA 200600877A EA 200600877 A1 EA200600877 A1 EA 200600877A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nanoparticles
drug delivery
composition
nanoparticle
polysaccharide
Prior art date
Application number
EA200600877A
Other languages
English (en)
Russian (ru)
Inventor
Веред Розенбергер
Найоми Молдавски
Моше Флэшнер-Барак
Э. Итзхак Лернер
Original Assignee
Тева Фармасьютикал Индастриз, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриз, Лтд. filed Critical Тева Фармасьютикал Индастриз, Лтд.
Publication of EA200600877A1 publication Critical patent/EA200600877A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA200600877A 2003-10-31 2004-10-28 Наночастицы для доставки лекарств EA200600877A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51632403P 2003-10-31 2003-10-31
PCT/US2004/036172 WO2005041933A1 (en) 2003-10-31 2004-10-28 Nanoparticles for drug delivery

Publications (1)

Publication Number Publication Date
EA200600877A1 true EA200600877A1 (ru) 2006-12-29

Family

ID=34549527

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600877A EA200600877A1 (ru) 2003-10-31 2004-10-28 Наночастицы для доставки лекарств

Country Status (10)

Country Link
US (1) US20050170004A1 (enExample)
EP (1) EP1680087A1 (enExample)
JP (1) JP2007509981A (enExample)
KR (1) KR20060097020A (enExample)
AU (1) AU2004285553B2 (enExample)
CA (1) CA2541445A1 (enExample)
EA (1) EA200600877A1 (enExample)
IL (1) IL174748A0 (enExample)
NZ (1) NZ546379A (enExample)
WO (1) WO2005041933A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
EP1459065B1 (en) * 2001-12-04 2010-07-28 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
NZ578727A (en) * 2004-06-25 2011-03-31 Brigham & Womens Hospital Proteosome compositions and methods for treating neurological disorders
HRP20160455T1 (hr) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
US8324641B2 (en) * 2007-06-29 2012-12-04 Ledengin, Inc. Matrix material including an embedded dispersion of beads for a light-emitting device
US20060172942A1 (en) * 2005-02-02 2006-08-03 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
US20060240463A1 (en) * 2005-04-25 2006-10-26 Rappaport Family Institute For Research In The Medical Sciences Markers associated with the therapeutic efficacy of glatiramer acetate
DE102005044400A1 (de) * 2005-09-16 2007-03-22 Capsulution Nanoscience Ag Verfahren zur Verkapselung und kontrollierten Freisetzung von schwer wasserlöslichen (hydrophoben) flüssigen und festen Wirkstoffen
AR063704A1 (es) 2006-09-14 2009-02-11 Makhteshim Chem Works Ltd Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones
WO2008032327A2 (en) * 2006-09-14 2008-03-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Organic nanoparticles obtained from microemulsions by solvent evaporation
US11246831B2 (en) 2007-03-30 2022-02-15 Particle Sciences, Inc. Particle formulations and uses thereof
WO2009070298A1 (en) * 2007-11-28 2009-06-04 Teva Pharmaceutical Industries, Ltd. Method of delaying the onset of clinically definite multiple sclerosis
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
IN2012DN00311A (enExample) 2009-07-09 2015-05-08 Oshadi Drug Administration Ltd
ES2351756B1 (es) * 2009-07-28 2011-10-05 Universidad Del Pais Vasco Nanopartículas lipídicas para terapia génica.
RS55607B1 (sr) 2009-08-20 2017-06-30 Yeda Research & Development Company Ltd Niskofrekventna terapija glatiramer acetatom
US20120177741A1 (en) * 2009-09-29 2012-07-12 Eyegate Pharmaceuticals, Inc. Positively-charged poly (d,l-lactide-co-glycolide) nanoparticles and fabrication methods of the same
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
WO2011080733A1 (en) 2010-01-04 2011-07-07 Mapi Pharma Limited Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
US20120039814A1 (en) * 2010-08-13 2012-02-16 Sample Jennifer L Topical Compositions and Methods of Detection and Treatment
US10758630B2 (en) * 2010-08-13 2020-09-01 The Johns Hopkins University Topical compositions and methods of detection and treatment
EA025780B1 (ru) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
MX2014004309A (es) 2011-10-10 2015-07-06 Teva Pharma Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
TWI483747B (zh) * 2012-05-29 2015-05-11 Univ Nat Chiao Tung 口服式藥物載體及其製備方法
US9724304B2 (en) * 2012-06-14 2017-08-08 Temple University—Of the Commonwealth System of Higher Education Nanospheres for therapeutic agent delivery
WO2014058976A2 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
CN111544601A (zh) 2012-10-30 2020-08-18 粒子科学有限公司 具有靶向部分的药物递送粒子制剂
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US10493122B2 (en) * 2014-03-17 2019-12-03 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
AU2017225481A1 (en) * 2016-03-01 2018-09-13 Fundacio Hospital Universitari Vall D'hebron-Institut De Recerca System for thermotherapy treatment or prevention of antimicrobial resistant or biofilm infections
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
JP2024509950A (ja) 2021-03-11 2024-03-05 89バイオ,インコーポレイテッド 変異体fgf-21ペプチドpeg化コンジュゲートを含む液体製剤
CN117120070B (zh) * 2021-03-11 2024-11-15 89生物公司 包含突变型fgf-21肽peg化缀合物的液体制剂
US11878025B2 (en) * 2021-09-06 2024-01-23 Slayback Pharma Llc Pharmaceutical compositions of mifepristone

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
AU658608B2 (en) * 1991-03-25 1995-04-27 Astellas Pharma Europe B.V. Topical preparation containing a suspension of solid lipid particles
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
ES2093562B1 (es) * 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
JP2001503735A (ja) * 1996-07-03 2001-03-21 ユニバーシティ オブ ピッツバーグ 親水性活性試薬のためのエマルジョン処方物
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US6537246B1 (en) * 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US20030170313A1 (en) * 1997-10-09 2003-09-11 Ales Prokop Micro-particulate and nano-particulate polymeric delivery system
US7101575B2 (en) * 1998-03-19 2006-09-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly
AU761205B2 (en) * 1998-03-30 2003-05-29 Skyepharma Canada Inc. Composition and method of preparing microparticles of water-insoluble substances
DE19819273A1 (de) * 1998-04-30 1999-11-11 Pharmatec International S Giul Pharmazeutische Ciclosporin-Formulierung mit verbesserten biopharmazeutischen Eigenschaften, erhöhter physikalischer Qualität und Stabilität sowie Verfahren zur Herstellung
US6514938B1 (en) * 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6355270B1 (en) * 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
US6355271B1 (en) * 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
CA2372461A1 (en) * 1999-05-07 2000-11-16 Pharmasol Gmbh Medicament vehicle for the controlled administration of an active agent, produced from lipid matrix-medicament conjugates
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US7195780B2 (en) * 2002-10-21 2007-03-27 University Of Florida Nanoparticle delivery system
US6482439B2 (en) * 1999-12-29 2002-11-19 Nanodelivery, Inc. Drug delivery system exhibiting permeability control
DE10001172A1 (de) * 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
US7022663B2 (en) * 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
SE0002822L (sv) * 2000-08-04 2002-01-29 Microdrug Ag Elektropulver
US6887493B2 (en) * 2000-10-25 2005-05-03 Adi Shefer Multi component controlled release system for oral care, food products, nutraceutical, and beverages
DK1345597T3 (da) * 2000-12-27 2007-12-10 Ares Trading Sa Amfifile lipidanopartikler til peptid- og/eller proteininkorporering
WO2003000236A1 (en) * 2001-06-23 2003-01-03 Lyotropic Therapeutics, Inc Particles with improved solubilization capacity
KR100566911B1 (ko) * 2001-06-25 2006-04-03 주식회사 삼양사 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체
US7125568B2 (en) * 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
WO2003062372A2 (en) * 2001-10-02 2003-07-31 The Regents Of The University Of California Nanoparticle assembled hollow spheres
US7311926B2 (en) * 2002-12-20 2007-12-25 Battelle Memorial Institute Biocomposite materials and methods for making the same
WO2005048435A1 (de) * 2003-11-13 2005-05-26 Sew-Eurodrive Gmbh & Co. Kg Kompaktantrieb
HRP20160455T1 (hr) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene

Also Published As

Publication number Publication date
AU2004285553A1 (en) 2005-05-12
JP2007509981A (ja) 2007-04-19
AU2004285553B2 (en) 2009-12-10
KR20060097020A (ko) 2006-09-13
CA2541445A1 (en) 2005-05-12
WO2005041933A1 (en) 2005-05-12
US20050170004A1 (en) 2005-08-04
IL174748A0 (en) 2006-08-20
NZ546379A (en) 2010-04-30
EP1680087A1 (en) 2006-07-19

Similar Documents

Publication Publication Date Title
CY1120564T1 (el) Υδατικα εναιωρηματα tmc278
CY1113003T1 (el) Ευσταθη παρασκευασματα laquinimod
MX2010007462A (es) Metodos y composiciones para administracion oral de agentes terapeuticos de peptidos y proteinas.
EA200401252A1 (ru) Микрочастицы лекарственных веществ
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
CY1109861T1 (el) Διαδερμικο θεραπευτικο συστημα για την ασθενεια του παρκινσον που προκαλει υψηλα επιπεδα πλασματος της ροτιγοτινης
WO2005065646A3 (en) Novel drug compositions and dosage forms
WO2004082628A3 (en) Improved bioavailability and improved delivery of acidic pharmaceutical drugs
WO2005055945A3 (en) Mucoadhesive drug delivery devices and methods of making and using thereof
WO2004054542A3 (en) Oral drug delivery system comprising high viscosity liquid carrier materials
ATE471144T1 (de) Intranasale verabreichung von schnell wirkendem insulin
HRP20060240T3 (hr) Intranazalni pripravak rotigotina
DE60326859D1 (de) Arzneimittelverabreichung
EE200200522A (et) Toimeainega konjugeerunud ensüüm-lõhustuv peptiid, seda sisaldav farmatseutiline kompositsioon ningühendi kasutamine kasvajavastase ravimina
DE60212693D1 (de) Formulierung von aminosäuren und riboflavin zur verringerung der toxischen effekte der zytotoxischen chemotherapie
NO20062051L (no) Farmasoytisk virkestoffinneholdende formulering med belegg
ATE464883T1 (de) Geschmacksabdeckende formulierung mit einer retardierten wirkstoffformulierung und/oder schnell löslichem cyclodextrin
ATE507818T1 (de) Orale verabreichung eines calcitonins
DE602004023093D1 (de) N mit einem abgabemittel in mikronisierter form
CL2008002353A1 (es) Compuestos derivados de 7h-indolo[2,1-a][2]benzazepina; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
WO2005117895A8 (en) Compositions comprising meloxicam
WO2006026592A3 (en) Oral administration of poorly absorbed drugs, methods and compositions related thereto
WO2005041936A3 (en) Methods of treatment of cancer using a composition comprising a cytotoxic drug and a porous carrier material